“…Hiroshige Fujishiro, MD, PhD, 21,22 Toshinori Nakamura, MD, 15 Kentaro Mizuno, MD, 23 Takahiko Inagaki, MD, 24,25 Eiichi Katsumoto, MD, 26 Hiroaki Tomita, MD, PhD, 27 Kazutaka Ohi, MD, PhD, 28 Hiroyuki Muraoka, MD, PhD, 29 Kiyokazu Atake, MD, PhD, 12 Hitoshi Iida, MD, 30 Tatsuya Nagasawa, MD, PhD, 28 Junichi Fujita, MD, PhD, 31 Satoshi Yamamura, MD, 32 Toshiaki Onitsuka, MD, PhD, 33 Atsunobu Murata, MS, 34 Yoichiro Takayanagi, MD, PhD, 35 Hokuto Noda, MD, 36 Yukiko Matsumura, MD, 37 Kenji Takezawa, MD, PhD, 38 Jun-ichi Iga, MD, PhD, 39 Kayo Ichihashi, MD, 40 Kazuyoshi Ogasawara, MD, PhD, 21,41 Hisashi Yamada, MD, PhD, 4,42 Ken Inada, MD, PhD 29 and Ryota Hashimoto, MD, PhD 4,43 * Aim: Although treatment guidelines for pharmacological therapy for schizophrenia and major depressive disorder have been issued by the Japanese Societies of Neuropsychopharmacology and Mood Disorders, these guidelines have not been well applied by psychiatrists throughout the nation. To address this issue, we developed the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' integrated education programs for psychiatrists to disseminate the clinical guidelines.…”